RTP Mobile Logo

Neil Love, MD

LaFargue CJ et al. Exploring and comparing adverse events between PARP inhibitors. Lancet Oncol 2019;20(1):e15-8. Abstract

Kathleen Moore, MD

Berek JS et al. Safety and dose modification for patients receiving niraparib. Ann Oncol 2018;29(8):1784-92. Abstract

Burger RA et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011;365(26):2473-83. Abstract

Coleman RL et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;390(10106):1949-61. Abstract

Gonzalez-Martin A et al. A randomized, double-blind phase 3 trial of niraparib maintenance treatment in patients with HRD+ advanced ovarian cancer after response to front-line platinum-based chemotherapy. Proc ASCO 2016;Abstract TPS5606.

Hodgson DR et al. Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes. Br J Cancer 2018;119(11):1401-9. Abstract

Kondrashova O et al. Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. Nat Commun 2018;9(1):3970. Abstract

Konstantinopoulos PA et al. Homologous recombination deficiency: Exploiting the fundamental vulnerability of ovarian cancer. Cancer Discov 2015;5(11):1137-54. Abstract

Ledermann J et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012;366(15):1382-92. Abstract

Litton J et al. EMBRACA: A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician’s choice of therapy in patients with advanced breast cancer and a germline BRCA mutation. San Antonio Breast Cancer Symposium 2017;Abstract GS6-07.

Moore KN et al. Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial. Proc ESMO 2018;Abstract LBA7_PR.

Moore KN et al. QUADRA: A phase 2, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) who have received ≥3 prior chemotherapy regimens. Proc ASCO 2018;Abstract 5514.

Norquist B et al. Mutations in homologous recombination genes and outcomes in ovarian carcinoma patients in GOG 218: An NRG Oncology/Gynecologic Oncology Group Study. Clin Cancer Res 2018;24(4):777-83. Abstract

Pujade-Lauraine E et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): A double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2017;18(9):1274-84. Abstract

Vergote I et al. Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients. Eur J Cancer 2016;69:127-34. Abstract

Melinda Telli, MD

Chen JH et al. Magnetic resonance imaging in predicting pathological response of triple negative breast cancer following neoadjuvant chemotherapy. J Clin Oncol 2007;25(35):5667-9. Abstract

Litton JK et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med 2018;379(8):753-63. Abstract

McLornan DP et al. Applying synthetic lethality for the selective targeting of cancer. N Engl J Med 2014;371(18):1725-35. Abstract

Robson ME et al. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol 2019;[Epub ahead of print]. Abstract

Robson ME et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 2017;377(6):523-33. Abstract

Roy R et al. BRCA1 and BRCA2: Different roles in a common pathway of genome protection. Nat Rev Cancer 2011;12(1):68-78. Abstract

Telli ML et al. Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer. Breast Cancer Res Treat 2018;171(1):21-31. Abstract

Telli ML et al. Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer. Breast Cancer Res Treat 2018;168(3):625-30. Abstract

Vinayak S et al. Durability of clinical benefit with niraparib + pembrolizumab in patients with advanced triple-negative breast cancer beyond BRCA: (TOPACIO/Keynote-162). San Antonio Breast Cancer Symposium 2018;Abstract PD5-02.

Michael Pishvaian, MD, PhD

Aguirre AJ et al. Real-time genomic characterization of advanced pancreatic cancer to enable precision medicine. Cancer Discov 2018;8(9):1096-111. Abstract

Bailey P et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 2016;531(7592):47-52. Abstract

Bang YJ et al. Randomized, double-blind phase II trial with prospective classification by ATM protein level to evaluate the efficacy and tolerability of olaparib plus paclitaxel in patients with recurrent or metastatic gastric cancer. J Clin Oncol 2015;33(33):3858-65. Abstract

Biankin AV et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 2012;491(7424):399-405. Abstract

Bouwman P, Jonkers J. Molecular pathways: How can BRCA-mutated tumors become resistant to PARP inhibitors? Clin Cancer Res 2014;20(3):540-7. Abstract

Collisson EA et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med 2011;17(4):500-3. Abstract

Golan T et al. Phase II study of olaparib for BRCAness phenotype in pancreatic cancer. Gastrointestinal Cancers Symposium 2018;Abstract 297.

Helleday T et al. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer 2008;8(3):193-204. Abstract

Kaufman B et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 2015;33(3):244-50. Abstract

Lal S et al. WEE1 inhibition in pancreatic cancer cells is dependent on DNA repair status in a context dependent manner. Sci Rep 2016;6:33323. Abstract

Lord CJ, Ashworth A. BRCAness revisited. Nature 2016;16(2):110-20. Abstract

Lowery MA et al. Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma. Eur J Cancer 2018;89:19-26. Abstract

Lowery MA et al. An emerging entity: Pancreatic adenocarcinoma associated with a known BRCA mutation: Clinical descriptors, treatment implications, and future directions. Oncologist 2011;16(10):1397-402. Abstract

Mateo J et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med 2015;373(18):1697-708. Abstract

Min A et al. AZD6738, a novel oral inhibitor of ATR, induces synthetic lethality with ATM deficiency in gastric cancer cells. Mol Cancer Ther 2017;16(4):566-77. Abstract

Nickoloff JA et al. Drugging the cancers addicted to DNA repair. J Natl Cancer Inst 2017;109(11):djx059. Abstract

O’Carrigan B et al. Phase I trial of a first-in-class ATR inhibitor VX-970 as monotherapy (mono) or in combination (combo) with carboplatin (CP) incorporating pharmacodynamics (PD) studies. Proc ASCO 2016;Abstract 2504.

O’Reilly EM et al. Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma. Cancer 2018;124(7):1374-82. Abstract

Peng G, Lin SY. Exploiting the homologous recombination DNA repair network for targeted cancer therapy. World J Clin Oncol 2011;2(2):73-9. Abstract

Pishvaian MJ et al. Molecular profiling of patients with pancreatic cancer: Initial results from the Know Your Tumor initiative. Clin Cancer Res 2018;24(20):5018-27. Abstract

Pishvaian MJ et al. BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer. Br J Cancer 2017;116(8):1021-6. Abstract

Rowe BP, Glazer PM. Emergence of rationally designed therapeutic strategies for breast cancer targeting DNA repair mechanisms. Breast Cancer Res 2010;12(2):203. Abstract

Strickland KC et al. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget 2016;7(12):13587-98. Abstract

Thijssen R et al. Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia. Blood 2016;128(4):574-83. Abstract

Toledo LI et al. A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations. Nat Struct Mol Biol 2011;18(6):721-7. Abstract

Waddell N et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 2015;518(7540):495-501. Abstract

Wang Z et al. Comutations in DNA damage response pathways serve as potential biomarkers for immune checkpoint blockade. Cancer Res 2018;78(22):6486-96. Abstract

Witkiewicz AK et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun 2015;6:3744. Abstract

Emmanuel S Antonarakis, MD

Abida W et al. Preliminary results from TRITON2: A phase 2 study of rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination repair (HRR) gene alterations. Proc ESMO 2018;Abstract 793PD.

Carney B et al. Target engagement imaging of PARP inhibitors in small-cell lung cancer. Nat Commun 2018;9(1):176. Abstract

Chowdhury S et al. Genomic profiling of circulating tumour DNA (ctDNA) and tumour tissue for the evaluation of rucaparib in metastatic castration-resistant prostate cancer (mCRPC). Proc ESMO 2018;Abstract 795PD.

Clarke N et al. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: A randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol 2018;19(7):975-86. Abstract

Fong PC et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361(2):123-34. Abstract

Fraser M et al. Genomic hallmarks of localized, non-indolent prostate cancer. Nature 2017;541(7637):359-64. Abstract

Isaacsson Velho P et al. Intraductal/ductal histology and lymphovascular invasion are associated with germline DNA-repair gene mutations in prostate cancer. Prostate 2018;78(5):401-7. Abstract

Karzai F et al. Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations. J Immunother Cancer 2018;6(1):141. Abstract

Mateo J et al. DNA-repair defects and olaparib in metastatic prostate cancer. N Engl J Med 2015;373(18):1697-708. Abstract

Marshall CH et al. Differential response to olaparib treatment among men with metastatic castration-resistant prostate cancer harboring BRCA1 or BRCA2 versus ATM mutations. Eur Urol 2019;[Epub ahead of print]. Abstract

Pritchard CC et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med 2016;375(5):443-53. Abstract

Robinson D et al. Integrative clinical genomics of advanced prostate cancer. Cell 2015;161(5):1215-28. Abstract

Schweizer MT et al. Genomic characterization of ductal adenocarcinoma of the prostate. Proc ASCO 2018;Abstract 5030.

Smith MR et al. Phase II study of niraparib in patients with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Preliminary results of GALAHAD. Genitourinary Cancers Symposium 2019;Abstract 202.

Yu EY et al. Keynote-365 cohort a: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC). Genitourinary Cancers Symposium 2019;Abstract 145.